Clin Osteol 2008; 13(3): 91-96

Influence of body weight and serum adipocytokines on bone mineral density and some parameters of bone metabolism in postmenopausal womenOriginal contributions

Z. Krivošíková, V. Spustová, K. Štefíková, M. Gajdoš, R. Dzúrik

Osteoporosis and obesity are continuously growing in prevalence. A longstanding clinical practice has pointed out, that obese women do not get osteoporosis; however, some studies have challenged that tenet. The aim of our study was to investigate the relation betwe­ en obesity, serum adipocytokines and bone metabolism in postmenopausal women. In a group of 123 postmenopausal women, lower incidence of osteoporosis was confirmed in obese women (9,9 %) in comparison with non-obese women (21,6 %). Significantly higher leptin and RANKL concentrations as well as lower OPG/RANKL ratio were found in obese women. There was significant positive correlation between leptin and femoral T-score. Using regression analysis, positive correlation between femoral T-score and OPG/RANKL ratio was detected. OPG and PTH/OPG ratio were associated with leptin. On the basis of bone mineral density mea­ surements, the influence of obesity to bone density in postmenopausal women could be considered to be affirmative. On the other hand, the concentrations of key regulation cytokines and a of obesity on bone density.

Keywords: obesity, osteoporosis, bone mass density, leptin

Published: December 11, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krivošíková Z, Spustová V, Štefíková K, Gajdoš M, Dzúrik R. Influence of body weight and serum adipocytokines on bone mineral density and some parameters of bone metabolism in postmenopausal women. Osteologický bulletin. 2008;13(3):91-96.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rosen CJ, Bouxsein ML. Mechanism of disease ne? Nat Clin Pract Rheumatol. 2006;2[1]:35-43. Go to original source...
    2. Hsu YH, Venners SA, Terwedoe HA, et al. relation ofbody composition, fat ma and serum lipids to osteoporotic fractures and bone mineral density in chinese men and women. Am J Clin Nutr. 2006;83:146-54. Go to original source...
    3. Albala C, Yaney M, Devoto E, et al. Obesity as a protective factor for postme pausal osteoporosis. Int J Obes Relat Metab Disord. 1996;20[11]:1027-32.
    4. Melton LJ, Kan SH, Frye MA, et al. Epidemiology of vertebral fractures in wo­ men. Am J Epidemiol. 1989;129:1000-11. Go to original source...
    5. Wang MC, Bachrach LK, M. Van Loan M, et al. The relative contributions of le­ an tissue mass and fat mass to bone density in young women. Bone. 2005; 37(4):474-81. Go to original source...
    6. Fruhbeck G, Gómez-Ambrosi J, Muruzábal FJ, et al. The adipocyte: a model for integration of endocrine and metabolic signaling i Am J Physiol Endocrinol Metab. 2001;280:E827-E847. Go to original source...
    7. Thomas T. Leptin: a potential mediato tissue. Joint Bone Spine. 2003;70:18-21. Go to original source...
    8. Khosla S. Leptin-central or peripheral to the regulation of bone metabolism? docrinology. 2002;143[11]:4161-4164. Go to original source...
    9. Longcope C, Baker S. Androgen and estrogen dynamics: Relationship with age, weight and menopausal satatus. J Clin Endocrinol Metab. 1993;76:601-604. Go to original source...
    10. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res. 2002;57:385 409. Go to original source...
    11. Reid IR 31:547-555.
    12. Holloway WR, Collier FM, Aitke J Bone Miner Res. 2002;17:200-209. Go to original source...
    13. Thomas T, Burguera B. I ner Res. 2002;17:1563-1569. Go to original source...
    14. Welt C, Chan J, Bullen J, et al. Recombinant hu talamic amenorrhea. N Engl J Med. 2004;351:987-997. Go to original source...
    15. Yang DC, Tsay HJ, Lin SH, et al. cAMP/PKA regulates osteogenesis, a sis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by supressing leptin. Plos ONE. 2008;3[2]:e1540. Go to original source...
    16. Kim SM, Kim SH, Lee JR, et al. Associations of leptin receptor polymorphi Lys109Arg and Gln223Arg with serum leptin profile and bone mineral density in Korean women. Am J Obstet Gynecol. 2008; in press. Go to original source...
    17. Lorentzon M, Landin K, Mellstrom D, et al. Leptin is a negative independent p dictor of areal BMD and cortical bone size in young adult sweedish male. 2006,21:1871-1878.
    18. Richards JB, Valdes AM, Burling K, et al.. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab. 2007;92:1517-23. Go to original source...
    19. Jurimäe J, Rembel K, Jurimäe T, Rehand M. Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res. 2005;37:297-302. Go to original source...
    20. Jurimäe J, Jurimäe T. Plasma adiponectin concentration in healthy pre- a menopausal women: relationship with body composition, bone mineral and meta­ bolic variables. AmJ Physiol Endocrinol Metab. 2007;293:E42-7. Go to original source...
    21. Misra M, Miller KK, Cord J, et al. Relationships between serum adipokines, in­ sulin levels and bone density in girls with anorexia nervosa. J Clin Endocrinol tab. 2007;92:2046-52. Go to original source...
    22. Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts via the MAPK signaling pathway. J Bone Miner Res 2006;21:1648-56. Go to original source...
    23. Luo XH, Guo LJ,Yuan LQ, et al. Adiponectin stimulates human osteoblast feration and differentiation via the MAPK signaling pathway. Exp Cell Res. 2005;309:99-109. Go to original source...
    24. Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors pressed in bone-forming cells. Bone. 2004;35:842-9. Go to original source...
    25. Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005;331:520-6. Go to original source...
    26. Oh KW, Lee WY, Rhee EJ, et al. The relationship between resistin, leptin, a nectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endoc­ rinol (Oxf). 2005;63:131-138. Go to original source...
    27. Peng XD, Xie H, Zhao Q, et al. Relationship between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone mineral markers in C nese men. Clinica Chimica Acta. 2008;387:31-35. Go to original source...
    28. An JJ, Han DH, Kim DM, et al. Expression and regulation of osteoprotegerin in adipose tissue. Yonsei Med J. 2007;48[5]:765-772. Go to original source...
    29. Ppadopouli AE, Klonaris CN, Theocharis SE. Role of OPG/RANKL/RANK axis on the vasculature. Histol Histopathol. 2008;23:497-506.
    30. Samelson EJ, Broe KE, Demissie S, et al. Increased plasma osteoprotegerin con­ centrations are associated with rinol Metab. 2008 Feb; in press. Go to original source...
    31. Secchiero P, Corallini F, f^ndolfi A, et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute dothelial cell dysfunction. Am J Pathol. 2006 Dec;169[6]:2236^4. Go to original source...
    32. Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, et al. sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialy­ sis patients. J Endocrinol Invest. 2007 Oct;30[9]:762-6. Go to original source...
    33. Findlay D, Chehade M, Tsangari H, et al. Circulating RANKL is related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther. 2008 Jan 8; in press. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.